Stewart, A. and Phillips, R.J.M. and Dempsey, G. (1998) Pharmacotherapy for people with Alzheimer's disease: a Markov-cycle evaluation of five years' therapy using donepezil. International Journal of Geriatric Psychiatry, 13 (7). pp. 445-453. ISSN 0885-6230. (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided)
|The full text of this publication is not available from this repository. (Contact us about this Publication)|
This article combines data from a clinical trial of donepezil with costing figures to evaluate expected direct costs of care over 5 years after diagnosis of Alzheimer's disease (AD) for patients aged 75 years and over at diagnosis. A Markov model simulates the progression of elderly persons through changing levels of severity. The model compares three treatment regimes for each of two patient groups; mild AD at start of treatment; moderate AD at start of treatment. Patients are followed until 5 years after the start of the treatment. Despite the acquisition costs, use of donepezil is approximately cost-neutral for both 5 mg and 10 mg treatment groups and for patients initially at either mild or moderate states of illness. Expected costs are slightly higher than for the placebo group, but higher expenditure on drugs is partly offset by lower costs of care consequent on treated patients not declining as rapidly as those untreated. The model showed that donepezil patients spent less time in the state of severe dementia, where costs of care are higher. Sensitivity analysis on key assumptions demonstrated that expected costs were highly dependent on discount rate and, more significantly, on the mortality rate.
|Divisions:||Faculties > Social Sciences > School of Social Policy Sociology and Social Research > Personal Social Services Research Unit|
|Depositing User:||Rosalyn Bass|
|Date Deposited:||21 May 2011 00:51|
|Last Modified:||07 Aug 2012 11:05|
|Resource URI:||https://kar.kent.ac.uk/id/eprint/27002 (The current URI for this page, for reference purposes)|